FILANA THERAPEUTICS INC
FLNANASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $0.39 β $3.45
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 48.3M
- Next Earnings
- 2027-03-02
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -0.7
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.87
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β99.0%
FILANA THERAPEUTICS INC
FLNAAbout FILANA THERAPEUTICS INC
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board
AUSTIN, Texas, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA), a biotechnology company focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced th

Filana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient Cells
Findings provide new insight into simufilam's effects on cellular stress responses and mitochondrial function New research demonstrates a 37% reduction in elevated ATF4, consistent with attenuation of the ATF4-associated

Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, to

Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward
The U.S. Food and Drug Administration (FDA) on Tuesday removed a clinical hold on the investigational new drug application for Filana Therapeutics, Inc. (NASDAQ:FLNA).

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organization, has identified clinical trial sites, and is recruiting potential inv